Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
Not Applicable
Recruiting
- Conditions
- HER2-positive Advanced Malignant Solid Tumors
- Interventions
- Biological: Anti-HER2 CAR-T cells
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- UTC Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06658951
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Malignant MesotheliomaOvary CancerBreast Cancer FemaleBile Duct CancerPancreatic CancerColorectal CancerRectal Cancer
- Interventions
- Biological: UCMYM802 Injection
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- UTC Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06256055
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath